HANSOH PHARMA (03692): XIN YUE (Inalizumab Injection) received the second indication approval from the National Medical Products Administration and was issued a drug registration certificate.
Hanssen Pharmaceuticals (03692) announced that on August 26, 2025, the innovative drug Xinyue (Inalitro...
HANSOH PHARMA (03692) announced that on August 26, 2025, the innovative drug Xinyue (Inerizumab monoclonal antibody injection) has been granted a drug registration certificate by the National Medical Products Administration (NMPA) of China, approving an additional indication: for use in adult patients with immunoglobulin G4-related diseases (IgG4-RD). This is the second approved indication for Xinyue, which had previously been included in the NMPA's priority review and approval process on February 8, 2025.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): RSS0393 ointment approved for clinical trials.
MAPLELEAF EDU (01317) spent 575,500 Hong Kong dollars on September 4 to repurchase 1,426,000 shares.
LINKLOGIS-W (09959) spent HK$9.77 million on September 4th to repurchase 3.53 million shares.
Jiangsu Hengrui Pharmaceuticals (01276): RSS0393 ointment approved for clinical trials.
MAPLELEAF EDU (01317) spent 575,500 Hong Kong dollars on September 4 to repurchase 1,426,000 shares.
LINKLOGIS-W (09959) spent HK$9.77 million on September 4th to repurchase 3.53 million shares.
RECOMMEND
“King of Phones in Africa” Faces Disruption as Xiaomi Surges and Transsion Slows
03/09/2025
Global Government Bond Sell-Off Pushes U.S. 30-Year Treasury Yield Back to 5% – What’s Driving the Move?
03/09/2025
Gold Climbs Above $3,600 to Record High as Central Bank Holdings Exceed U.S. Treasuries for First Time in 30 Years
03/09/2025
